{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-276062","form_type":"8-K","ticker":"CRBP","cik":"0001595097","company_name":"Corbus Pharmaceuticals Holdings, Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.865142+00:00","generated_at":"2026-05-16T21:12:11.065347+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Corbus Q3 net loss $23.3M ($1.90/sh); cash $104M; CRB-701 ORR 47.6% in HNSCC","bullets":["Net loss of $23.3M ($1.90 diluted EPS) vs $13.8M ($1.15) in Q3 2024; operating expenses up $8.9M.","Cash, equivalents $104M at Sep 30; raised $73.8M net in Oct-Nov offering extending runway into 2028.","CRB-701 ESMO data: ORR 47.6% (HNSCC), 37.5% (cervical), 55.6% (mUC) at 3.6 mg/kg; registrational study planned mid-2026.","CRB-913 SAD/MAD study on track; Ph1b in obese patients to start Q4 2025.","CRB-601 Phase 1 dose escalation ongoing; first participant dosed Dec 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-276062","json":"https://secwatch.observer/filing/0001193125-25-276062.json","markdown":"https://secwatch.observer/filing/0001193125-25-276062.md","text":"https://secwatch.observer/filing/0001193125-25-276062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595097/000119312525276062/0001193125-25-276062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595097/000119312525276062/crbp-20251112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:12:11.065347+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}